ORYN 1051

ORYN 1051 is a macrocyclic peptide therapeutic developed by Oryn Therapeutics. It belongs to a class of biomolecules called Orynotides, which are inspired by theta defensins—naturally occurring circular peptides found in Old World monkeys. These peptides are characterized by high stability, excellent bioavailability, low toxicity, and low immunogenicity. ORYN 1051 is being developed as a subcutaneous injection for the treatment of inflammatory diseases such as Crohn's disease and potentially other immune-mediated conditions. The drug has demonstrated anti-inflammatory properties in preclinical models[1][2]. Its mechanism of action likely involves modulation of immune cell activity and inhibition of inflammatory pathways; however, specific molecular targets have not been explicitly disclosed in public sources.